Myriad Partners with Tesaro on Companion Diagnostic for Tesaro's PARP Inhibitor

Myriad Genetics, Inc. today announced that Tesaro, Inc. will use Myriad's novel HRD (homologous recombination deficiency) test to identify tumor types that may respond to its investigational poly-ADP ribose polymerase (PARP) inhibitor, niraparib, currently in Phase 3 clinical development.

Myriad Genetics, Inc.

today announced that Tesaro, Inc. will use Myriad's novel HRD (homologous recombination deficiency) test to identify tumor types that may respond to its investigational poly-ADP ribose polymerase (PARP) inhibitor, niraparib, currently in Phase 3 clinical development. Specific terms of the deal were not disclosed.

The research agreement with Tesaro is Myriad's fifth collaboration with a major pharmaceutical company to evaluate HRD. Myriad estimates the global market for an HRD test could exceed $3 billion as oncologists move toward personalized medicine and targeted therapies.

Read the complete press release here:

http://on.mktw.net/1fVrzio

Source: MarketWatch